- Title
- Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
- Creators
- Nicoletta Colombo - University of Milano-BicoccaCoraline Dubot - Institute CurieDomenica Lorusso - Fdn Policlin Univ A Gemelli IRCCS, Rome, ItalyM. Valeria Caceres - Inst Oncol Angel H Roffo, Buenos Aires, DF, ArgentinaKosei Hasegawa - College Station Medical CenterRonnie Shapira-Frommer - College Station Medical CenterKrishnansu S. Tewari - OrangePamela Salman - Oncovida Canc Ctr, Providencia, ChileEdwin Hoyos Usta - OncoMedEduardo Yanez - Universidad de La FronteraMahmut Gumus - Istanbul Medeniyet UniversityMivael Olivera Hurtado de Mendoza - Inst Nacl Enfermedades Neoplas, Lima, PeruVanessa Samouelian - Université de MontréalVincent Castonguay - Université du QuébecAlexander Arkhipov - College Station Medical CenterSarper Toker - MerckKan Li - MerckStephen M. Keefe - MerckBradley J. Monk - Creighton UniversityKEYNOTE-826 Investigators
- Publication Details
- Obstetrical & gynecological survey, Vol.77(1), pp.30-31
- Publisher
- Lippincott Williams & Wilkins
- Number of pages
- 2
- Identifiers
- 991005969166302656
- Academic Unit
- Obstetrics & Gynecology
- Language
- English
- Resource Type
- Journal article
Journal article
Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
Obstetrical & gynecological survey, Vol.77(1), pp.30-31
01/01/2022
Related links
Metrics
7 Record Views